company background image
TECH

Bio-Techne NasdaqGS:TECH Stock Report

Last Price

US$366.35

Market Cap

US$14.4b

7D

-0.4%

1Y

-10.5%

Updated

21 May, 2022

Data

Company Financials +
TECH fundamental analysis
Snowflake Score
Valuation0/6
Future Growth3/6
Past Performance4/6
Financial Health6/6
Dividends0/6

TECH Stock Overview

Bio-Techne Corporation, together with its subsidiaries, develops, manufactures, and sells life science reagents, instruments, and services for the research, and diagnostics and bioprocessing markets worldwide.

Rewards

Earnings are forecast to grow 14.75% per year

Earnings grew by 22.4% over the past year

Risk Analysis

TECH passed our risk checks.

Bio-Techne Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Bio-Techne
Historical stock prices
Current Share PriceUS$366.35
52 Week HighUS$543.85
52 Week LowUS$335.02
Beta1.23
1 Month Change-13.72%
3 Month Change-8.64%
1 Year Change-10.50%
3 Year Change85.22%
5 Year Change228.86%
Change since IPO14,196.59%

Recent News & Updates

May 13
Estimating The Fair Value Of Bio-Techne Corporation (NASDAQ:TECH)

Estimating The Fair Value Of Bio-Techne Corporation (NASDAQ:TECH)

How far off is Bio-Techne Corporation ( NASDAQ:TECH ) from its intrinsic value? Using the most recent financial data...

Mar 23

Bio-Techne - Exceptional Leverage To Biopharma Growth, And Priced Accordingly

Bio-Techne has used M&A and internal manufacturing know-how to vault itself into the cell/gene therapy research and bioproduction market, a $3B+ market today growing at over 20% a year. GMP protein manufacturing will be a significant near-term driver for the business, but offerings in cell separation/activation, gene editing, and analytics are not trivial. Beyond the cell/gene therapy market, Bio-Techne has leveraged itself to growth opportunities in molecular diagnostics (including liquid biopsy) and spatial biology. Valuation is extreme, with Bio-Techne trading at around 16.5x forward revenue, but M&A in this sector has gone off at even higher multiples.

Shareholder Returns

TECHUS Life SciencesUS Market
7D-0.4%1.4%-2.7%
1Y-10.5%-8.5%-12.9%

Return vs Industry: TECH underperformed the US Life Sciences industry which returned -9.5% over the past year.

Return vs Market: TECH exceeded the US Market which returned -12.7% over the past year.

Price Volatility

Is TECH's price volatile compared to industry and market?
TECH volatility
TECH Average Weekly Movement6.0%
Life Sciences Industry Average Movement10.8%
Market Average Movement7.9%
10% most volatile stocks in US Market16.9%
10% least volatile stocks in US Market3.0%

Stable Share Price: TECH is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 6% a week.

Volatility Over Time: TECH's weekly volatility (6%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
19762,600Chuck Kummethhttps://www.bio-techne.com

Bio-Techne Corporation, together with its subsidiaries, develops, manufactures, and sells life science reagents, instruments, and services for the research, and diagnostics and bioprocessing markets worldwide. The company operates through two segments, Protein Sciences, and Diagnostics and Genomics. The Protein Sciences segment provides biological reagents used in various aspects of life science research, diagnostics, and cell and gene therapy, such as cytokines and growth factors, antibodies, small molecules, tissue culture sera, and cell selection technologies.

Bio-Techne Fundamentals Summary

How do Bio-Techne's earnings and revenue compare to its market cap?
TECH fundamental statistics
Market CapUS$14.37b
Earnings (TTM)US$225.38m
Revenue (TTM)US$1.08b

63.8x

P/E Ratio

13.4x

P/S Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
TECH income statement (TTM)
RevenueUS$1.08b
Cost of RevenueUS$341.24m
Gross ProfitUS$735.16m
Other ExpensesUS$509.78m
EarningsUS$225.38m

Last Reported Earnings

Mar 31, 2022

Next Earnings Date

n/a

Earnings per share (EPS)5.74
Gross Margin68.30%
Net Profit Margin20.94%
Debt/Equity Ratio15.2%

How did TECH perform over the long term?

See historical performance and comparison

Dividends

0.3%

Current Dividend Yield

22%

Payout Ratio

Valuation

Is Bio-Techne undervalued compared to its fair value and its price relative to the market?

Valuation Score

0/6

Valuation Score 0/6

  • Below Fair Value

  • Significantly Below Fair Value

  • PE vs Industry

  • PE vs Market

  • PEG Ratio

  • PB vs Industry


63.77x

Price to Earnings (PE) ratio

Share Price vs. Fair Value

Below Fair Value: TECH ($366.35) is trading above our estimate of fair value ($363.82)

Significantly Below Fair Value: TECH is trading above our estimate of fair value.


Price To Earnings Ratio

PE vs Industry: TECH is poor value based on its PE Ratio (63.8x) compared to the US Life Sciences industry average (32.1x).

PE vs Market: TECH is poor value based on its PE Ratio (63.8x) compared to the US market (15.5x).


Price to Earnings Growth Ratio

PEG Ratio: TECH is poor value based on its PEG Ratio (4.3x)


Price to Book Ratio

PB vs Industry: TECH is overvalued based on its PB Ratio (8.4x) compared to the US Life Sciences industry average (2.2x).


Future Growth

How is Bio-Techne forecast to perform in the next 1 to 3 years based on estimates from 11 analysts?

Future Growth Score

3/6

Future Growth Score 3/6

  • Earnings vs Savings Rate

  • Earnings vs Market

  • High Growth Earnings

  • Revenue vs Market

  • High Growth Revenue

  • Future ROE


14.8%

Forecasted annual earnings growth

Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: TECH's forecast earnings growth (14.8% per year) is above the savings rate (1.9%).

Earnings vs Market: TECH's earnings (14.8% per year) are forecast to grow faster than the US market (12.5% per year).

High Growth Earnings: TECH's earnings are forecast to grow, but not significantly.

Revenue vs Market: TECH's revenue (13.4% per year) is forecast to grow faster than the US market (7.8% per year).

High Growth Revenue: TECH's revenue (13.4% per year) is forecast to grow slower than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: TECH's Return on Equity is forecast to be low in 3 years time (17.7%).


Past Performance

How has Bio-Techne performed over the past 5 years?

Past Performance Score

4/6

Past Performance Score 4/6

  • Quality Earnings

  • Growing Profit Margin

  • Earnings Trend

  • Accelerating Growth

  • Earnings vs Industry

  • High ROE


19.6%

Historical annual earnings growth

Earnings and Revenue History

Quality Earnings: TECH has high quality earnings.

Growing Profit Margin: TECH's current net profit margins (20.9%) are lower than last year (21.7%).


Past Earnings Growth Analysis

Earnings Trend: TECH's earnings have grown by 19.6% per year over the past 5 years.

Accelerating Growth: TECH's earnings growth over the past year (22.4%) exceeds its 5-year average (19.6% per year).

Earnings vs Industry: TECH earnings growth over the past year (22.4%) exceeded the Life Sciences industry 21%.


Return on Equity

High ROE: TECH's Return on Equity (12.6%) is considered low.


Financial Health

How is Bio-Techne's financial position?

Financial Health Score

6/6

Financial Health Score 6/6

  • Short Term Liabilities

  • Long Term Liabilities

  • Debt Level

  • Reducing Debt

  • Debt Coverage

  • Interest Coverage

Financial Position Analysis

Short Term Liabilities: TECH's short term assets ($593.1M) exceed its short term liabilities ($166.8M).

Long Term Liabilities: TECH's short term assets ($593.1M) exceed its long term liabilities ($419.7M).


Debt to Equity History and Analysis

Debt Level: TECH's net debt to equity ratio (1.7%) is considered satisfactory.

Reducing Debt: TECH's debt to equity ratio has reduced from 39.4% to 15.2% over the past 5 years.

Debt Coverage: TECH's debt is well covered by operating cash flow (132%).

Interest Coverage: TECH's interest payments on its debt are well covered by EBIT (25.6x coverage).


Balance Sheet


Dividend

What is Bio-Techne current dividend yield, its reliability and sustainability?

Dividend Score

0/6

Dividend Score 0/6

  • Notable Dividend

  • High Dividend

  • Stable Dividend

  • Growing Dividend

  • Earnings Coverage

  • Future Dividend Coverage


0.35%

Current Dividend Yield

Dividend Yield vs Market

Notable Dividend: TECH's dividend (0.35%) isn’t notable compared to the bottom 25% of dividend payers in the US market (1.57%).

High Dividend: TECH's dividend (0.35%) is low compared to the top 25% of dividend payers in the US market (4.09%).


Stability and Growth of Payments

Stable Dividend: TECH is not paying a notable dividend for the US market, therefore no need to check if payments are stable.

Growing Dividend: TECH is not paying a notable dividend for the US market, therefore no need to check if payments are increasing.


Earnings Payout to Shareholders

Earnings Coverage: TECH is not paying a notable dividend for the US market.


Cash Payout to Shareholders

Cash Flow Coverage: TECH is not paying a notable dividend for the US market.


Discover strong dividend paying companies

Management

How experienced are the management team and are they aligned to shareholders interests?

4.2yrs

Average management tenure


CEO

Chuck Kummeth (61 yo)

9.08yrs

Tenure

US$15,889,897

Compensation

Mr. Charles R. Kummeth, also known as Chuck, has been the Chief Executive Officer and President of Bio-Techne Corporation since April 1, 2013 and served as its Chief Financial Officer since January 2014. M...


CEO Compensation Analysis

Compensation vs Market: Chuck's total compensation ($USD15.89M) is about average for companies of similar size in the US market ($USD13.27M).

Compensation vs Earnings: Chuck's compensation has increased by more than 20% in the past year.


Leadership Team

Experienced Management: TECH's management team is considered experienced (4.2 years average tenure).


Board Members

Experienced Board: TECH's board of directors are considered experienced (9.1 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: TECH insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.


Top Shareholders

Company Information

Bio-Techne Corporation's employee growth, exchange listings and data sources


Key Information

  • Name: Bio-Techne Corporation
  • Ticker: TECH
  • Exchange: NasdaqGS
  • Founded: 1976
  • Industry: Life Sciences Tools and Services
  • Sector: Pharmaceuticals & Biotech
  • Implied Market Cap: US$14.373b
  • Shares outstanding: 39.23m
  • Website: https://www.bio-techne.com

Number of Employees


Location

  • Bio-Techne Corporation
  • 614 McKinley Place N.E.
  • Minneapolis
  • Minnesota
  • 55413
  • United States

Listings


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2022/05/21 00:00
End of Day Share Price2022/05/20 00:00
Earnings2022/03/31
Annual Earnings2021/06/30


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.